Culturing and Expansion of "Clinical Grade" Neural Stem Cells from the Fetal Human Central Nervous System.

Autor:	Gelati M; IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy. m.gelati@operapadrepio.it., Profico DC; IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy., Ferrari D; Department of Biotechnology and Biosciences, University of Milano-Bicocca, Milan, Italy., Vescovi AL; IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Foggia, Italy. vescovia@gmail.com.
Jazyk:	angličtina
Zdroj:	Methods in molecular biology (Clifton, N.J.) [Methods Mol Biol] 2022; Vol. 2389, pp. 57-66.
DOI:	10.1007/978-1-0716-1783-0_5
Abstrakt:	NSCs have been demonstrated to be very useful in grafts into the mammalian central nervous system to investigate the exploitation of NSC for the therapy of neurodegenerative disorders in animal models of neurodegenerative diseases. To push cell therapy in CNS on stage of clinical application, it is necessary to establish a continuous and standardized, clinical grade (i.e., produced following the good manufacturing practice guidelines) human neural stem cell lines.In this chapter we will illustrate some of the protocols for the production and characterization routinely used into our GMP "cell factory" for the production of "clinical grade" human neural stem cell lines already in use in clinical trials on neurodegenerative diseases, particularly amyotrophic lateral sclerosis (ALS- Clinicaltrials.gov number NCT01640067) and secondary progressive multiple sclerosis (SPMS- Clinicaltrials.gov number NCT03282760). (© 2022. Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu